title: Regulation of the ligand binding activity of the human very low density lipoprotein receptor by protein kinase C-dependent phosphorylation.
abstract: The very low density lipoprotein receptor (VLDL-R) binds and internalizes several ligands, including very low density lipoprotein (VLDL), urokinase-type plasminogen activator:plasminogen activator inhibitor type 1 complexes, lipoprotein lipase, and the 39-kDa receptor-associated protein that copurifies with the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor. Although several agonists regulate VLDL-R mRNA and/or protein expression, post-transcriptional regulation of receptor activity has not been described. Here, we report that the ligand binding activity of the VLDL-R in THP-1 monocytic cells, endothelial cells, smooth muscle cells, and VLDL-R-transfected HEK 293 cells is diminished after treatment with phorbol 12-myristate 13-acetate. This response was blocked by inhibitors of protein kinase C (PK-C), including a specific inhibitor of the PK-C beta II isoform, and was associated with phosphorylation of serine residues in the cytoplasmic domain of the receptor. Culture of endothelial cells in the presence of high glucose concentrations, which stimulate diacylglycerol synthesis and PK-C beta II activation, also induced a PK-C-dependent loss of VLDL-R ligand binding activity. Taken together, these studies demonstrate that the ligand binding activity of the VLDL-R is regulated by PK-C-dependent phosphorylation and that hyperglycemia may diminish VLDL-R activity.
authors.affiliation: Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
authors.forename: R
authors.initials: R
authors.lastname: Sakthivel
authors.forename: J C
authors.initials: JC
authors.lastname: Zhang
authors.forename: D K
authors.initials: DK
authors.lastname: Strickland
authors.forename: M
authors.initials: M
authors.lastname: Gåfvels
authors.forename: K R
authors.initials: KR
authors.lastname: McCrae
mesh_terms: D002460:Cell Line; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D004789:Enzyme Activation; D005947:Glucose / Q000494:pharmacology; D026541:Heymann Nephritis Antigenic Complex; D006801:Humans; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D008024:Ligands; D008562:Membrane Glycoproteins / Q000378:metabolism; D010766:Phosphorylation; D010768:Phosphoserine / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011973:Receptors, LDL / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D017384:Sequence Deletion; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014162:Transfection; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
chemical_list: D026541:Heymann Nephritis Antigenic Complex; D007527:Isoenzymes; D008024:Ligands; D008562:Membrane Glycoproteins; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D011973:Receptors, LDL; C036053:VLDL receptor; D010768:Phosphoserine; D011493:Protein Kinase C; D014568:Urokinase-Type Plasminogen Activator; D005947:Glucose; D013755:Tetradecanoylphorbol Acetate